Business Context and Reporting Period
This Form 8-K, filed on May 29, 2020, by CytomX Therapeutics, Inc. (CTMX), reports the availability of oral and poster presentations at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program. The filing details preliminary clinical data for the Company's Probody drug conjugates (PDCs) and checkpoint inhibitors, specifically CX-2029, CX-2009, and CX-072, as well as partner data for BMS-986249.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and scientific data.
Material Changes and Clinical Updates
CX-2029 (CD71 Targeting PDC)
- Target: CD71 (transferrin receptor) with MMAE payload; developed in partnership with AbbVie.
- Enrollment: 45 patients with advanced solid tumors enrolled in eight dose cohorts (0.1 to 5 mg/kg) as of April 20, 2020.
- Efficacy: Three confirmed partial responses observed in 17 response-evaluable patients at doses ≥ 2 mg/kg (two in squamous non-small cell lung cancer, one in head and neck squamous cell cancer).
- Safety: Generally well tolerated up to 3 mg/kg. Most common treatment-related adverse events (TRAEs) were infusion reactions, anemia, and neutropenia/leukopenia. No treatment-related deaths reported.
- Next Steps: Recommended Phase 2 dose is 3 mg/kg every three weeks. Four expansion cohorts planned: HNSCC, SqNSCLC, esophageal carcinoma, and diffuse large B cell lymphoma.
CX-2009 (CD166 Targeting PDC)
- Target: CD166 with DM4 payload.
- Enrollment: 96 patients enrolled in Phase 1 dose escalation as of April 20, 2020.
- Efficacy: Durable activity observed in HER2-negative breast cancer. Two confirmed partial responses in hormone receptor-positive patients; three unconfirmed responses in triple-negative breast cancer (TNBC). Clinical benefit rates were 39% at 16 weeks and 35% at 24 weeks.
- Safety: Recommended Phase 2 dose is 7 mg/kg every three weeks. No dose-limiting toxicities (DLTs) reported up to 7 mg/kg. Ocular, neuropathic, and hepatic toxicities increased at doses > 7 mg/kg.
- Status: A Phase 2 expansion study in HER2-negative breast cancer was temporarily paused in March 2020 due to the COVID-19 pandemic.
CX-072 (Anti-PD-L1 Probody)
- Enrollment: 114 patients in the 10 mg/kg monotherapy expansion arm; 27 patients in the combination arm with ipilimumab.
- Efficacy: Durable activity in IO-sensitive tumors (TNBC, anal/cutaneous squamous cell carcinoma, high mutational burden). One complete response in anal squamous cell carcinoma in the combination arm (patient on study >2 years).
- Safety: Long-term patients (≥6 months) experienced fewer immune-related adverse events (irAEs) and no Grade 3+ irAEs.
BMS-986249 (Partner Data)
- Target: Anti-CTLA-4 Probody (partner: Bristol Myers Squibb).
- Status: Generally well tolerated as monotherapy and in combination with nivolumab. A randomized trial in advanced melanoma has been initiated.
Guidance, Outlook, and Risks
Management indicated an intention to resume the CX-2009 clinical program as soon as practicable following the COVID-19-related pause. The filing includes standard forward-looking statements regarding the potential benefits, safety, and efficacy of product candidates, noting that actual results may differ due to substantial risks and uncertainties inherent in clinical development.
Investor Verification Checklist
- Verify the timeline for resuming patient enrollment in the paused CX-2009 Phase 2 expansion study.
- Confirm the specific enrollment criteria and start dates for the four planned CX-2029 expansion cohorts.
- Review the detailed safety data regarding anemia and neutropenia management for CX-2029 at the 3 mg/kg dose.
- Monitor the progress of the randomized BMS-986249 trial in advanced melanoma.
- Check subsequent filings for updates on the long-term durability of responses in the CX-072 combination arm.